Quectel Launches High Performance Single-Band GNSS Positioning Module LC76G With Ultra-low Power Consumption
20.6.2022 15:30:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announced the release of its LC76G module, a single-band compact GNSS module featuring fast and accurate location performance as well as ultra-low power consumption. The LC76G has already entered mass production with sufficient supply to meet the needs of the global positioning market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220620005121/en/
Quectel LC76G module, a single-band compact GNSS module featuring fast and accurate location performance as well as ultra-low power consumption
Based on the Airoha AG3352 platform, the LC76G can concurrently receive and process signals from all constellations (GPS, GLONASS, BeiDou, Galileo and QZSS), which in combination with the support of SBAS greatly increases the number of visible satellites and enhances positioning accuracy. The LC76G module can receive signals from up to 47 satellites and achieve 1.5m (CEP50 open-sky) positioning accuracy representing a 40% improvement over previous generations of devices.
Available in a cost-optimized version as well as a low-power version, the LC76G low-power version consumes less than 9mA @3V with all 4 constellations enabled allowing for a 72% reduction in power required than previously possible.
This makes the LC76G extremely attractive for battery operated devices such as wearable personal trackers, wildlife and livestock tracking, Toll tags, portable container trackers as well as a host of traditional markets such as Shared Mobility and low-cost asset trackers.
Featuring an internal SAW filter and integrated LNA, the LC76G can be connected directly to a passive patch antenna and provides filtering against unwanted interference ensuring excellent performance even while driving through dense urban canyons.
Integrated AGNSS technology EPO™, is supported on the LC76G module and reduces the time to first fix (TTFF) with a hot start taking less than 1 second, a warm start within 2 seconds, while the cold start can obtain accurate tracking fixes within 15 seconds. The faster GNSS fixes make it possible to use accurate positioning and navigation services anytime and anywhere with a smaller power budget than previously possible.
While EPO requires manual download of predicted orbits, the LC76G also supports EASY™ (Embedded Assist System) where predicted orbit information is collected directly from the Satellites and provides for up to 3 days of accelerated fixes.
Both EPO and Easy™ are available for each constellation allowing for faster TTFF and reduced dependency on any particular constellation.
Featuring an LCC form factor and an ultra-compact size of 10.1mm × 9.7mm ×2.4mm, the footprint of the LC76G is compatible with other industry solutions as well as Quectel’s legacy L76 and L76-LB modules, allowing for a smooth migration of existing designs to the latest low power GNSS technology.
In addition, Quectel offers a wide range of off-the-shelf and customized high-performance antennas which boost wireless connectivity significantly. Quectel’s LC76G can be combined with a selection of GNSS L1 antennas to enable various positioning requirements. Customized connector type and cable length as well as comprehensive antenna design and test support are also available to facilitate customer product development.
The LC76G will be on display at Embedded World Nuremberg on Booth No 171, Hall 5, June 21- 23 2022.
About Quectel:
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.
For more information: www.Quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005121/en/
Contact information
Ashley Liu
media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
